Evidence map›Paper›PMID 38063401›Full record

ArticleAntimicrobial agents and chemotherapy2024

Antigiardial and antiamebic activities of fexinidazole and its metabolites: new drug leads for giardiasis and amebiasis.

Jose Ignacio Escrig, Yukiko Miyamoto, Alejandro Delgado Aznar, Lars Eckmann, Anjan Debnath

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antiprotozoal Activity AgainstMolecules (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jose Ignacio EscrigCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, California, USA.
Yukiko MiyamotoDepartment of Medicine, University of California San Diego , La Jolla, California, USA.
Alejandro Delgado AznarCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, California, USA.
Lars EckmannDepartment of Medicine, University of California San Diego , La Jolla, California, USA.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , La Jolla, California, USA.ORCID 0000-0001-9294-3927
University of California San Diego · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
NCATS NIH HHS KL2 TR001444NCATS NIH HHS UL1 TR001442NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

The intestinal parasites

Indexed as

AmebiasisEntamoeba histolyticaGiardia lambliaGiardiasisNitroimidazolesAnimalsHumansMetronidazoleMiceNitroreductasesfexinidazoleMetronidazoleNitroimidazolesNitroreductasesantiparasitic agentsEntamoeba histolyticaGiardia

Identifiers

PMID38063401
PMCPMC10777846
OpenAlexW4389478617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.